Should I buy Apollo Hospitals stock in 2025?

Why trust HelloSafe?

At HelloSafe, our expert has been monitoring the performance of Apollo Hospitals for more than three years. Every month, hundreds of thousands of users in India rely on us to interpret market trends and highlight the most promising investment opportunities. Our analyses are provided purely for informational purposes and do not represent investment advice. In line with our ethical charter, we have never received, and will never accept, any form of payment from Apollo Hospitals.

What is Apollo Hospitals?

How much is Apollo Hospitals stock?

The price of Apollo Hospitals stock is rising this week. As of today, the stock trades at ₹6,965.00, reflecting a 24-hour gain of 0.28% and a weekly increase of 1.01%. Apollo Hospitals boasts a market capitalization of ₹100,132 crore, with an average 3-month daily trading volume ensuring good liquidity.

The current P/E Ratio stands at 76.44, the dividend yield is 0.23%, and the stock’s beta is 1.07, suggesting slightly higher volatility than the broader market. Investors should note that while valuations are elevated, the company's strong growth trajectory and sector leadership continue to attract market attention.

Our full analysis on Apollo Hospitals stock

Having thoroughly reviewed Apollo Hospitals' latest quarterly financial results and systematically analysed the company’s stock performance over the past three years, we integrated proprietary algorithms leveraging a spectrum of indicators—ranging from key financial ratios and technical signals to broader sector data and competitor benchmarks. This data-rich analysis provides an up-to-the-minute perspective on the investment case for Apollo Hospitals within the Indian healthcare sector. So, why might Apollo Hospitals stock once again become a strategic entry point into healthcare and health-tech leadership in 2025?

Recent Performance and Market Context

Apollo Hospitals has delivered resilient outperformance, both operationally and on the stock market, amidst a dynamic healthcare sector landscape in India. As of May 5, 2025, the company’s shares trade at ₹6,965.00, a 17.1% return over the past year and a stellar 77.9% three-year gain, against the backdrop of major indices posting single to low-double-digit returns. The 1-month return stands at an impressive 11.1%, reflecting renewed investor conviction post the Q3 FY25 results.

This robust price action aligns with several catalysts:

• Q3 FY25 earnings: Net profit surged 51.8% YoY to ₹379 crore, on a 14% revenue rise and margin expansion.
• Digital inflection: Apollo HealthCo achieved its first profitable quarter, with digital businesses rapidly scaling user metrics.
• Sector tailwinds: Healthcare spending continues to accelerate, with the Indian government’s prioritization of public health and rising private demand, further boosted by medical tourism inflows.
• Favourable macro backdrop: Healthcare has remained relatively insulated from macroeconomic volatility—a defensive and secular growth theme.

With the sector poised for reinvestment, supported by increased government allocations and regulatory stability, Apollo’s diversified revenue streams position it advantageously within India’s evolving healthcare market.

Technical Analysis

A survey of Apollo Hospitals’s technical chart structure paints a notably constructive picture. Current price levels at ₹6,965.00 remain firmly above the key short and long-term moving averages:

Sustained trading above all major moving averages confirms a persistent bullish undertone. Support at ₹6,800 and ₹6,600 demonstrates strong institutional buying interest, while resistances at ₹7,100 and ₹7,400 delineate realistic technical upside targets.

The RSI-14 reading at 56.6 implies the stock sits in a balanced momentum phase—neither overbought nor oversold—signaling further upside may develop with limited risk of immediate exhaustion. The MACD, slightly bearish at -17.01, suggests some consolidation, creating a potential new base for an upward move. Coupled with a modestly elevated beta of 1.07, Apollo’s price structure suggests medium-term entry points could capture significant upside if technical resistance zones are breached.

Fundamental Analysis

Apollo Hospitals’ long-term investment thesis remains anchored in its impressive financial trajectory as India’s largest integrated healthcare provider. The company continues to post best-in-class revenue growth, with a 15% CAGR over five years and Q3 FY25 revenues up 14% YoY to ₹5,527 crore. Profitability has outpaced top-line gains, as seen in the 24% YoY surge in EBITDA and stellar 51.8% growth in net profit.

Key metrics underscore Apollo’s leadership:

• ROCE: 15.11%
• ROE: 13.3%
• EBITDA Margin (Healthcare Services): 24.1%

Strategic expansion across high-margin specialties—cardiac, oncology, neurosciences, gastro, and orthopedics—boosts blended margins and supports growing average revenue per occupied bed (ARPOB). Apollo’s pharmacy and digital businesses are outpacing legacy healthcare segment growth, with the digital vertical in particular reaching profitability for the first time, auguring structural margin gains ahead.

While current valuation multiples—P/E at 76.44, EV/EBITDA at 32.5x, and P/B at 13.35—reflect premium positioning, they are supported by robust growth visibility, high margin business, and an unparalleled competitive moat. In particular, Apollo’s market leadership, technological integration (notably with Microsoft for AI), and expanding private label product sales further justify sustained investor enthusiasm.

Volume and Liquidity

Trading liquidity in Apollo Hospitals remains robust, buoyed by a healthy average daily volume that signals strong market participation and institutional interest. The moderate float supports efficient price discovery and minimizes the risk of sharp, unanticipated moves. Persistent activity at elevated volume levels, even after recent price gains, is an important barometer of market confidence, suggesting that Apollo’s valuation remains dynamic with substantial absorption capacity for incremental buying.

Catalysts and Positive Outlook

Several concrete growth vectors enhance Apollo Hospitals’ forward prospects and underpin its long-term positive trajectory:

• Expansion: New flagship hospitals in Pune, Kolkata, Hyderabad, and Gurgaon to be commissioned in FY26, with further capacity coming online in high-value markets like Mumbai and Chennai over the next four years.
• Specialty revenue acceleration: Rapid expansion in high-margin specializations (Oncology +25% YoY; Neurosciences +23%; Gastro +20%).
• Digital transformation: Apollo 24/7 digital platform has crossed 2 million new user sign-ups; daily user engagement is up 25% YoY. Breakeven for the digital business is targeted as early as Q2/Q3 FY26.
• Insurance foray: The recent IRDAI license opens a scalable, high-margin vertical for Apollo, further embedding the brand in the Indian healthcare financing ecosystem.
• International diversification: Aggressive push into new geographies (Sri Lanka, Middle East, Iraq, Indonesia) to augment international patient revenues, and de-risk from overdependence on Bangladesh referrals.
• ESG and innovation: Collaborations with Microsoft for artificial intelligence implementation are modernizing care delivery and operational efficiency.

These catalysts—explicitly mapped and well-resourced—drive a virtuous cycle of revenue growth, margin expansion, and renewed investor attention.

Investment Strategies

Whether seeking exposure over the short, medium, or long-term, Apollo Hospitals’ current technical and fundamental configuration appears compelling:

• Short-term traders may find opportunities near technical support at ₹6,800 as a lower-risk re-entry, with tight stops and a clear eye towards a breakout above ₹7,100 resistance tied to upcoming quarterly results or fresh expansion news.
• Medium-term investors could prioritize the runup into the FY26 facility commissionings, and the anticipated digital business breakeven—each a substantial positive catalyst expected within 6–12 months.
• Long-term strategic investors are likely to benefit most from the company’s pan-India and international capacity buildout, rising dispersion into tech-driven health verticals, and Apollo’s leadership in pharmacy, diagnostics, and health insurance for the next decade.

With sector leadership reaffirmed and multiple catalysts converging in the near future, staggered entries—particularly at periods of technical consolidation—may optimize positioning for value creation.

Is it the Right Time to Buy Apollo Hospitals?

A cogent synthesis of Apollo Hospitals’ investment profile reveals an array of enduring strengths:

• Consistent outperformance on both revenue and profit growth, well above sector averages
• Leadership in high-margin specialties and a diversified health ecosystem (physical assets and digital platforms)
• Aggressively expanding capacity in fast-growing urban and specialty markets
• Digital and insurance segments unlocking new addressable markets and margin layers
• Technological innovation and ESG focus strengthening its enterprise value proposition

While premium valuations warrant a measured approach, the depth and breadth of Apollo’s growth engines, coupled with healthy balance sheet metrics, position the stock for further value creation. The technical landscape suggests near-term consolidation can serve as attractive entry points, with multiple upside catalysts on the horizon.

For Indian investors looking to participate in the next wave of healthcare sector expansion, Apollo Hospitals seems to represent an excellent opportunity, backed by both operational momentum and a future-ready business model. The ongoing sector transformation, combined with Apollo’s demonstrated execution and expansion strategy, justifies renewed interest and suggests the stock may be entering a new bullish phase for 2025 and beyond.

In summary, Apollo Hospitals stands out as a prime candidate for serious consideration by investors seeking exposure to a high-growth, innovation-driven leader at the cutting edge of Indian healthcare—offering both resilience and significant upside within a transforming market.

How to buy Apollo Hospitals stock in India?

Buying Apollo Hospitals stock online is a straightforward and secure process when you use a regulated broker in India. Investors can choose between two main approaches: traditional spot (cash) buying, where you own actual shares, or trading contracts for difference (CFDs), which allow you to speculate on price movements with or without leverage. Each method has its own risk-return profile and cost structure. In the following sections, you'll find clear explanations of each method—along with practical examples—to help you decide which suits your needs. A detailed broker comparison is provided further down the page.

Spot Buying

Spot (cash) buying means you purchase real Apollo Hospitals shares through your broker. The shares are held in your demat account, giving you actual ownership—they entitle you to potential dividends and voting rights. When buying shares on the Indian stock market (NSE), brokers typically charge a fixed commission per order; this might be around ₹20–₹30 per trade, plus negligible regulatory fees and GST.

Example

If Apollo Hospitals shares trade at ₹6,965.00 each, a ₹1,000 investment allows you to buy about 0.14 shares (rounded down, as most Indian brokers require buying at least 1 share—so you would likely need a larger initial amount). Assuming you invest ₹7,000 to buy 1 share, and pay a brokerage fee of ₹30:

• If the share price rises by 10%, your share is worth ₹7,661.50.
• Result: Gross gain of ₹696.50, or +10% on your investment, excluding fees.

If you invest less than the price of one share, some platforms may offer fractional shares, but this is not standard on the NSE.

Trading via CFD

CFD (Contract for Difference) trading lets you speculate on Apollo Hospitals’ price movements without owning the underlying share. With CFDs, you can use leverage to multiply your exposure—potentially amplifying both gains and losses. Costs typically include a spread (the small difference between the buy and sell price) and overnight financing fees if your position is held open beyond the trading day.

Example

Let’s say you open a ₹1,000 CFD position on Apollo Hospitals with 5x leverage. Your total exposure becomes ₹5,000.

• If the share price rises by 8%, your exposure grows to ₹5,400.
• Result: Gain is ₹400, a +40% return on your ₹1,000 stake (excluding spread and any overnight charges).

Remember, losses are also multiplied with leverage, and CFD trading is subject to additional risks compared to direct share ownership.

Final Advice

Before investing, it's essential to compare brokers’ fees, available tools, customer support, and whether they offer features like fractional share buying or leverage. Choose a method that aligns with your investment goals and risk tolerance—spot buying suits long-term investors seeking ownership, while CFDs can be an option for those comfortable with greater risk and short-term trading. To help you get started, check the broker comparison further down the page to find the platform that best matches your needs.

Application

Notes

Learn more

#1

Forex specialist

#1

Eightcap

Notes

4.9

Discover

5 things to know about Eightcap

Is EightCap reliable?

Yes, EightCap is a trusted platform regulated by ASIC (Australia) and FCA (United Kingdom). Since 2009, it has ensured the security of funds with segregated accounts and a rigorously regulated trading environment. If you are looking for a reliable broker to start with, EightCap is a safe bet, recognised in the industry.

Why choose EightCap?

EightCap combines performance and flexibility. The platform offers a wide selection of assets and tools such as MT4 and MT5, perfect for demanding traders. Are you a beginner? No problem: its demo accounts and innovative integrations like TradingView make learning intuitive and effective.

What are the fees at EightCap?

At EightCap, fees depend on the account you choose: Raw accounts display spreads from 0 pip, with a commission of $3.5 per lot. Standard accounts have slightly higher spreads but no commissions. No fees on deposits or withdrawals, for clear and controlled costs.

Who is EightCap for?

Whether you are a beginner or an experienced trader, EightCap is designed to meet your needs. Are you starting out? Take advantage of guides and demo accounts to understand the basics. Are you more advanced? Tools like MT5 and competitive spreads will allow you to go further in your strategies.

Is it easy to withdraw money from EightCap?

Withdrawing your earnings on EightCap is quick and easy. Requests are processed within 24 hours and you can use flexible options such as bank transfer, cards or e-wallets. Security and speed are at the heart of the service.

Is EightCap reliable?

Yes, EightCap is a trusted platform regulated by ASIC (Australia) and FCA (United Kingdom). Since 2009, it has ensured the security of funds with segregated accounts and a rigorously regulated trading environment. If you are looking for a reliable broker to start with, EightCap is a safe bet, recognised in the industry.

Why choose EightCap?

EightCap combines performance and flexibility. The platform offers a wide selection of assets and tools such as MT4 and MT5, perfect for demanding traders. Are you a beginner? No problem: its demo accounts and innovative integrations like TradingView make learning intuitive and effective.

What are the fees at EightCap?

At EightCap, fees depend on the account you choose: Raw accounts display spreads from 0 pip, with a commission of $3.5 per lot. Standard accounts have slightly higher spreads but no commissions. No fees on deposits or withdrawals, for clear and controlled costs.

Who is EightCap for?

Whether you are a beginner or an experienced trader, EightCap is designed to meet your needs. Are you starting out? Take advantage of guides and demo accounts to understand the basics. Are you more advanced? Tools like MT5 and competitive spreads will allow you to go further in your strategies.

Is it easy to withdraw money from EightCap?

Withdrawing your earnings on EightCap is quick and easy. Requests are processed within 24 hours and you can use flexible options such as bank transfer, cards or e-wallets. Security and speed are at the heart of the service.

#2

CFD specialist

#2

Avatrade

Notes

4.8

Discover

20% bonus on deposit

5 Things to Know About Avatrade

Is Avatrade reliable?

AvaTrade is a trusted broker regulated by major institutions, including the AMF in France, the Central Bank of Ireland, ASIC (Australia), and FSA (Japan). Active since 2006, it offers solid guarantees, including the segregation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.

Why choose Avatrade?

AvaTrade combines simplicity and expertise. Tutorials, demo accounts, and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities as you progress. You don’t need to be an expert: AvaTrade adapts to you.

What are the fees at Avatrade?

AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and inactivity costs that can be avoided with regular use. You can focus on learning and your investments without surprises when it comes to paying.

Who is Avatrade for?

AvaTrade is for everyone: beginners can take advantage of detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you are looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is an excellent choice.

Is it easy to withdraw money from Avatrade?

Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, wire transfers, or e-wallets. Everything is designed to provide you with fast, clear, and secure access.

Is Avatrade reliable?

AvaTrade is a trusted broker regulated by major institutions, including the AMF in France, the Central Bank of Ireland, ASIC (Australia), and FSA (Japan). Active since 2006, it offers solid guarantees, including the segregation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.

Why choose Avatrade?

AvaTrade combines simplicity and expertise. Tutorials, demo accounts, and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities as you progress. You don’t need to be an expert: AvaTrade adapts to you.

What are the fees at Avatrade?

AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and inactivity costs that can be avoided with regular use. You can focus on learning and your investments without surprises when it comes to paying.

Who is Avatrade for?

AvaTrade is for everyone: beginners can take advantage of detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you are looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is an excellent choice.

Is it easy to withdraw money from Avatrade?

Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, wire transfers, or e-wallets. Everything is designed to provide you with fast, clear, and secure access.

#3

Expert in Forex and CFD

#3

Vantage

Notes

4.8

Discover

50% bonus on 1st deposit

5 things to know about Vantage

Is Vantage reliable?

Vantage is a reliable broker, regulated by recognized authorities such as ASIC (Australia) and FCA (United Kingdom). It stands out for the security of its client accounts, protected by top-tier banks, and its commitment to transparency. With over 15 years of experience, Vantage is a trustworthy platform.

Why choose Vantage?

Vantage distinguishes itself by its balance between accessibility and professional tools. Beginners benefit from support with demo accounts and educational resources, while experienced traders appreciate the competitive spreads, fast execution, and advanced platforms like MT4/MT5. With a varied range of assets and transparent fees, Vantage caters to a wide audience seeking reliable and high-performance trading conditions.

What are the fees at Vantage?

The fees at Vantage are adapted to everyone. On ECN accounts, spreads start at 0 pip with a commission of $3 per lot. Standard accounts offer slightly higher spreads, but without commission. No deposit or withdrawal fees are applied, and the cost of inactivity is limited. With Vantage, you keep control of your costs to invest effectively.

Who is Vantage for?

Vantage is perfect for traders looking for professional conditions, while remaining accessible to beginners. If you want a fast platform, competitive fees and advanced tools, Vantage is an excellent choice. Whether you are learning or perfecting your strategies, you will find the necessary resources.

Is it easy to withdraw money from Vantage?

Withdrawing funds from Vantage is fast and secure. Requests are processed in less than 48 hours and you can choose between bank transfer, cards or electronic wallets. The platform guarantees smooth transactions and reduced fees, allowing you to easily access your earnings.

Is Vantage reliable?

Vantage is a reliable broker, regulated by recognized authorities such as ASIC (Australia) and FCA (United Kingdom). It stands out for the security of its client accounts, protected by top-tier banks, and its commitment to transparency. With over 15 years of experience, Vantage is a trustworthy platform.

Why choose Vantage?

Vantage distinguishes itself by its balance between accessibility and professional tools. Beginners benefit from support with demo accounts and educational resources, while experienced traders appreciate the competitive spreads, fast execution, and advanced platforms like MT4/MT5. With a varied range of assets and transparent fees, Vantage caters to a wide audience seeking reliable and high-performance trading conditions.

What are the fees at Vantage?

The fees at Vantage are adapted to everyone. On ECN accounts, spreads start at 0 pip with a commission of $3 per lot. Standard accounts offer slightly higher spreads, but without commission. No deposit or withdrawal fees are applied, and the cost of inactivity is limited. With Vantage, you keep control of your costs to invest effectively.

Who is Vantage for?

Vantage is perfect for traders looking for professional conditions, while remaining accessible to beginners. If you want a fast platform, competitive fees and advanced tools, Vantage is an excellent choice. Whether you are learning or perfecting your strategies, you will find the necessary resources.

Is it easy to withdraw money from Vantage?

Withdrawing funds from Vantage is fast and secure. Requests are processed in less than 48 hours and you can choose between bank transfer, cards or electronic wallets. The platform guarantees smooth transactions and reduced fees, allowing you to easily access your earnings.

Our 7 tips for buying Apollo Hospitals stock

The latest news about Apollo Hospitals

Apollo Hospitals reported stellar Q3 FY25 results with net profit up 51.8% year-on-year, highlighting robust performance. This strong profitability was driven by 14% year-on-year revenue growth to ₹5,527 crore and significant margin expansion, with EBITDA up 24% to ₹762 crore. The company’s healthcare services segment, contributing over half of its revenue, maintained healthy EBITDA margins above 24% and saw occupancy rates rise to 68%. Notably, the digital and pharmacy business recorded its first profitable quarter, showcasing successful operating leverage and strengthening prospects for sustained overall margin improvement.

The Apollo 24/7 digital platform demonstrated marked progress, with user metrics and profitability both improving significantly. The platform attracted 2 million new users in the last quarter and increased daily active users by 25% year-on-year, with gross merchandise value up 11%. For the first time, the digital segment turned EBITDA positive, signaling a maturing contribution from digital health services and buttressing the company’s ambitious strategy to leverage technology for patient engagement and operational efficiency. These developments further support Apollo’s stated target to achieve digital business breakeven by Q2 or Q3 of FY26.

Major expansion projects remain on track, with multiple new hospitals scheduled to open in key metropolitan locations through FY26. Facilities in Pune and Kolkata are slated for commissioning in H1 FY26, while Hyderabad and Gurgaon will follow in H2, with further oncology program expansions in Mumbai and Delhi areas. This expansion is expected to drive double-digit revenue growth, supported by India’s increasing demand for advanced healthcare services and Apollo’s leadership in high-margin specialty care such as oncology, neurosciences, and gastroenterology. Management commentary reflects confidence in maintaining growth despite short-term margin trade-offs linked to new capacity.

The company’s insurance vertical gained momentum as Apollo obtained IRDAI approval and announced plans to launch co-branded products with major insurers. This regulatory milestone enables Apollo to directly capture value from the rapidly growing Indian health insurance segment, which is expected to drive higher patient volumes and enhance overall margins. Collaboration with three life and three health insurers underscores the strategic intent to vertically integrate and diversify revenue sources, positioning Apollo as a more comprehensive healthcare platform for Indian consumers.

Market sentiment remains highly favorable, with a “Buy” consensus among analysts and an 11.9% implied upside from current share price levels. Recent technical indicators, including all major moving averages pointing bullish and the RSI in the neutral range, reflect ongoing investor confidence and steady trading momentum. Despite premium valuation multiples, Apollo’s track record of earnings growth, leadership in digital health, and aggressive scale-up plans continue to anchor positive outlooks among market participants in India.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.